Mount Sinai Beth Israel is a 799-bed teaching hospital in Manhattan. It is part of the Mount Sinai Health System, a nonprofit health system formed in September 2013 by the merger of Continuum Health Partners and Mount Sinai Medical Center, and an academic affiliate of the Icahn School of Medicine at Mount Sinai.

There are 799 beds in Beth Israel Medical Center.

During the past decade, Beth Israel Medical Center conducted 92 clinical trials. In the 10-year time frame, 92 clinical trials started and 108 clinical trials were completed, i.e. on average, 117.4% percent of trials that started reached the finish line to date. In the past 5 years, 25 clinical trials started and 53 clinical trials were completed. i.e. 212% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Beth Israel Medical Center" #1 sponsor was "National Institute of Allergy and Infectious Diseases (NIAID)" with 121 trials, followed by "Beth Israel Medical Center" with 29 trials sponsored, "Icahn School of Medicine at Mount Sinai" with 22 trials sponsored, "Radiation Therapy Oncology Group" with 21 trials sponsored and "Gilead Sciences" with 21 trials sponsored. Other sponsors include 232 different institutions and companies that sponsored additional 153 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Beth Israel Medical Center" #1 collaborator was "National Cancer Institute (NCI)" with 45 trials as a collaborator, "Glaxo Wellcome" with 10 trials as a collaborator, "National Institute of Neurological Disorders and Stroke (NINDS)" with 10 trials as a collaborator, "NRG Oncology" with 8 trials as a collaborator and "Bristol-Myers Squibb" with 7 trials as a collaborator. Other collaborators include 207 different institutions and companies that were collaborators in the rest 152 trials.

According to Clinical.Site data, the most researched conditions in "Beth Israel Medical Center" are "HIV Infections" (153 trials), "Breast Cancer" (19 trials), "Cystic Fibrosis" (16 trials), "Pulmonary Arterial Hypertension" (13 trials) and "Prostate Cancer" (10 trials). Many other conditions were trialed in "Beth Israel Medical Center" in a lesser frequency.

Most popular intervention types in "Beth Israel Medical Center" are "Drug" (315 trials), "Other" (43 trials), "Biological" (33 trials), "Device" (30 trials) and "Procedure" (30 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (48 trials), "Zidovudine" (28 trials), "Stavudine" (23 trials), "Lamivudine" (22 trials) and "Didanosine" (20 trials). Other intervention names were less common.

The vast majority of trials in "Beth Israel Medical Center" are 405 trials for "All" genders, 26 trials for "Female" genders and 12 trials for "Male" genders.

Currently, there are NaN active trials in "Beth Israel Medical Center". undefined are not yet recruiting, 18 are recruiting, 18 are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 353 completed trials in Beth Israel Medical Center, undefined suspended trials, and 39 terminated clinical trials to date.

Out of the total trials that were conducted in Beth Israel Medical Center, 29 "Phase 1" clinical trials were conducted, 154 "Phase 2" clinical trials and 129 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 14 trials, and there were also 84 trials that are defined as “Not Applicable".